EuroBiotech Report: Addiction data, J&J-Genmab, Basilea rejig, Zealand, CRUK and more


Welcome to the latest edition of our weekly EuroBiotech Report. Indivior (LON:INDV) took a big step toward bringing its once-a-month opioid dependence drug to market. The Reckitt Benckiser (LON:RB) spinout reported Phase III data on the program, sending its stock up 15% and positioning it to snag an approval by the end of 2017. Johnson & Johnson ($JNJ) and Genmab (CPH:GEN) are hoping to get their latest trip to FDA wrapped up much sooner. The pair are waiting on a priority review decision that could lead to the label for Darzalex being expanded in the coming months. Zealand Pharma (CPH:ZEAL) is also gearing up for talks with FDA. The Danish drugmaker wants to meet with the regulator to discuss Phase II data on its rival to Novo Nordisk’s ($NVO) GlucaGen. Basilea Pharmaceutica (SWX:BSLN) rejigged its early-stage pipeline, dropping an inhaled antibiotic while expanding a trial of its small molecule tumor checkpoint controller. Cancer Research UK began a Phase I/II bladder cancer trial of Astex Pharmaceuticals’ DNA methyltransferase inhibitor. And more.

1. Late-phase opioid addiction success sparks surge in Indivior stock price 

2. J&J files to expand Darzalex label, triggering another payout to Genmab

3. Zealand takes PhII data to FDA after going up against Novo’s incumbent

4. Basilea drops inhaled antibiotic, expands cancer program in early-stage rejig

5. CRUK pairs Astex's inhibitor with chemo for bladder cancer trial

And more articles of note >>